Article
Oncology
L. Paz-Ares, Y. Chen, N. Reinmuth, K. Hotta, D. Trukhin, G. Statsenko, M. J. Hochmair, M. Ozguroglu, J. H. Ji, M. C. Garassino, O. Voitko, A. Poltoratskiy, E. Musso, L. Havel, I Bondarenko, G. Losonczy, N. Conev, H. Mann, T. B. Dalvi, H. Jiang, J. W. Goldman
Summary: In extensive-stage small-cell lung cancer (ES-SCLC), durvalumab plus EP continues to improve overall survival (OS), while durvalumab plus tremelimumab plus EP shows numerical improvement but does not reach statistical significance.
Review
Medicine, Research & Experimental
Caterina Arru, Maria Rosaria De Miglio, Antonio Cossu, Maria Rosaria Muroni, Ciriaco Carru, Angelo Zinellu, Panagiotis Paliogiannis
Summary: Cancer immunotherapy with the combination of durvalumab and tremelimumab has shown some oncological advantages in comparison with traditional chemotherapies in certain subsets of tumors. However, consistent advantages over durvalumab monotherapy have not been demonstrated. Future well-designed studies with larger cohorts are needed to further investigate the potential benefits of this combination therapy.
ADVANCES IN THERAPY
(2021)
Article
Multidisciplinary Sciences
J. Capdevila, J. Hernando, A. Teule, C. Lopez, R. Garcia-Carbonero, M. Benavent, A. Custodio, A. Garcia-Alvarez, A. Cubillo, V. Alonso, A. Carmona-Bayonas, T. Alonso-Gordoa, G. Crespo, P. Jimenez-Fonseca, M. Blanco, A. Viudez, A. La Casta, I. Sevilla, A. Segura, M. Llanos, S. Landolfi, P. Nuciforo, J. L. Manzano
Summary: Single immune checkpoint blockade has limited efficacy in patients with NENs. However, dual checkpoint blockade with durvalumab and tremelimumab shows promising results in patients with advanced NENs of gastroenteropancreatic and lung origin. This study highlights the potential of durvalumab plus tremelimumab as a treatment option for NENs patients.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Marie Alt, Carlos Stecca, Yian Lin, Gbenga Kazeem, Erik T. Goluboff, Srikala S. Sridhar
Summary: This retrospective analysis of clinical trial data in patients with metastatic urothelial carcinoma (mUC) identified several baseline characteristics and laboratory measurements that were associated with long-term survival (LTS) following treatment with immune checkpoint inhibitors.
Article
Oncology
Yoo-Na Kim, Je-Gun Joung, Eunhyang Park, Jae-Weon Kim, Jung Bok Lee, Jinyeong Lim, Sunghoon Kim, Chel Hun Choi, Hee Seung Kim, Jongsuk Chung, Byoung-Gie Kim, Jung-Yun Lee
Summary: Choosing the right combination of drugs based on patient-specific biomarkers can improve treatment efficacy in ovarian cancer. However, the efficacy and safety of different combinations of PARP inhibitors have not been evaluated in ovarian cancer patients with HRR mutations. In this study, we compared two olaparib-based combinations in platinum-resistant ovarian cancer patients with HRR gene mutations and found similar response rates and manageable adverse events in both groups. We also identified biomarkers associated with treatment outcomes and proposed a comprehensive biomarker profiling approach to guide treatment selection. These findings have the potential to improve treatment outcomes in the PARP inhibitor era.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Gilberto de Castro Jr, Naiyer A. Rizvi, Peter Schmid, Konstantinos Syrigos, Claudio Martin, Nobuyuki Yamamoto, Ying Cheng, Vladimir Moiseyenko, Yvonne Summers, Ihor Vynnychenko, Sung Yong Lee, Maciej Bryl, Alona Zer, Mustafa Erman, Constanta Timcheva, Rajiv Raja, Kirsha Naicker, Urban Scheuring, Jill Walker, Helen Mann, Vikram Chand, Tony Mok
Summary: In the NEPTUNE study, first-line durvalumab plus tremelimumab did not show significant improvement in overall survival compared to chemotherapy in patients with metastatic NSCLC.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Neeta Somaiah, Anthony P. Conley, Edwin Roger Parra, Heather Lin, Behrang Amini, Luisa Solis Soto, Ruth Salazar, Carmelia Barreto, Honglei Chen, Swati Gite, Cara Haymaker, Elise F. Nassif, Chantale Bernatchez, Akash Mitra, John Andrew Livingston, Vinod Ravi, Dejka M. Araujo, Robert Benjamin, Shreyaskumar Patel, Maria A. Zarzour, Sharjeel Sabir, Alexander J. Lazar, Wei-Lien Wang, Najat C. Daw, Xiao Zhou, Christina L. Roland, Zachary A. Cooper, Jaime Rodriguez-Canales, Andrew Futreal, Jean-Charles Soria, Ignacio I. Wistuba, Patrick Hwu
Summary: This trial evaluates the efficacy and safety of durvalumab, an anti-PD-L1 drug, and tremelimumab, an anti-CTLA-4 drug, for multiple subtypes of metastatic sarcomas. The combination treatment demonstrates active potential for advanced or metastatic sarcoma and should be further investigated in specific subsets in future trials.
Article
Oncology
Emily M. Hinchcliff, Anne Knisely, Naomi Adjei, Bryan Fellman, Ying Yuan, Ami Patel, Cai Xu, Shannon N. Westin, Anil K. Sood, Pamela T. Soliman, Aaron Shafer, Nicole D. Fleming, David M. Gershenson, Raghunandan Vikram, Tharakeswara Bathala, David Vining, Dhakshina M. Ganeshan, Karen H. Lu, Charlotte C. Sun, Larissa A. Meyer, Amir A. Jazaeri
Summary: There was no significant difference in immune-related progression-free survival (irPFS) and median progression-free survival (PFS) between the sequential administration of tremelimumab and durvalumab and the combination treatment of these two drugs in patients with platinum-resistant high-grade serous ovarian cancer. The adverse events and patient-reported outcomes were similar in both treatment groups.
Article
Oncology
Neil H. Segal, Andrea Cercek, Geoffrey Ku, Abraham J. Wu, Andreas Rimner, Danny N. Khalil, Diane Reidy-Lagunes, John Cuaron, T. Jonathan Yang, Martin R. Weiser, Paul B. Romesser, Zsofia K. Stadler, Anna M. Varghese, Karuna Ganesh, Rona Yaeger, Louise C. Connell, David Faleck, Ghassan K. Abou-Alfa, Kathleen C. Mcauliffe, Pamela Vaiskauskas, Mark L. Solter, Martinique Ogle, Matthew J. Adamow, Aliya Holland, Pallavi Vedantam, Phillip Wong, Taha Merghoub, Efsevia Vakiani, Travis J. Hollmann, Krishna Juluru, Joanne F. Chou, Marinela Capanu, Joseph Erinjeri, Stephen Solomon, Yoshiya Yamada, Nancy Kemeny, Christopher H. Crane, Leonard B. Saltz
Summary: The combination of radiotherapy plus immune checkpoint inhibition did not meet the endpoint criteria for further study in mismatch repair-proficient metastatic colorectal cancer. However, there were instances of systemic immune augmentation and regression in nonirradiated lesions observed in some patients. Further studies on novel immunotherapy combinations and biomarkers predictive of abscopal responses are warranted.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Li Cheng, Todd Creasy, Fernanda Pilataxi, Lydia Greenlees, Luis Vence, Sriram Sridhar, Katie Streicher
Summary: The study investigated the effects of anti-PD-L1 antibody durvalumab (D) alone or in combination with the anti-CTLA-4 antibody tremelimumab (T) on non-small-cell lung carcinoma (NSCLC) tumors. The results showed an increase in interferon gamma (IFN-gamma) production with both D and D + T treatments, with additional upregulation of Th1/Th2 pathways with D + T. Additionally, there was a reduction in interleukin 10 (IL-10) production in response to D and D + T treatments.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Immunology
Jun Ni, Xiaoyan Si, Hanping Wang, Xiaotong Zhang, Li Zhang
Summary: This study evaluates the preliminary efficacy and safety of camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer (ES-SCLC) patients. The results show that IP/IC plus camrelizumab group has a median PFS of 10.25 months, and the objective response rate is 89.6%.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Nabendu Pore, Song Wu, Nathan Standifer, Maria Jure-Kunkel, Melissa de los Reyes, Yashaswi Shrestha, Rebecca Halpin, Raymond Rothstein, Kathy Mulgrew, Stephen Blackmore, Philip Martin, John Meekin, Matthew Griffin, Ina Bisha, Theresa A. Proia, Ricardo J. Miragaia, Ronald Herbst, Ashok Gupta, Shaad E. Abdullah, Rajiv Raja, Melanie M. Frigault, J. Carl Barrett, Phillip A. Dennis, Maria Libera Ascierto, Michael D. Oberst
Summary: Mutations in the STK11 gene can regulate resistance to PD-1/PD-L1 blockade in patients with nonsquamous non-small cell lung cancer. These mutations may lead to resistance to checkpoint blockade by affecting immune phenotype and immune checkpoints. Modulation of STAT3 signaling can reverse this resistance, suggesting potential combination therapies for STK11-mutant NSCLC.
Article
Oncology
Ying Cheng, Qing Zhou, Baohui Han, Yun Fan, Li Shan, Jianhua Chang, Si Sun, Jian Fang, Yuan Chen, Jianguo Sun, Gang Wu, Helen Mann, Kirsha Naicker, Norah Shire, Tony Mok, Gilberto de Castro Jr
Summary: The NEPTUNE study conducted prespecified exploratory analyses in a cohort of Chinese patients and found that first-line durvalumab plus tremelimumab (DT) showed a trend towards improved overall survival (OS) compared to chemotherapy in patients with PD-L1 expression < 1% and in the overall population.
Article
Oncology
Robin Kate Kelley, Bruno Sangro, William Harris, Masafumi Ikeda, Takuji Okusaka, Yoon-Koo Kang, Shukui Qin, David W-M Tai, Ho Yeong Lim, Thomas Yau, Wei-Peng Yong, Ann-Lii Cheng, Antonio Gasbarrini, Silvia Damian, Jordi Bruix, Mitesh Borad, Johanna Bendell, Tae-You Kim, Nathan Standifer, Philip He, Mallory Makowsky, Alejandra Negro, Masatoshi Kudo, Ghassan K. Abou-Alfa
Summary: This study evaluated the treatment regimens for patients with hepatocellular carcinoma and found that all regimens were tolerable and clinically active, with the T300 + D regimen showing the most favorable benefit-risk profile. Early expansion of CD8+ lymphocytes was associated with treatment response across arms.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Natasha B. Leighl, Mary W. Redman, Naiyer Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz, James L. Wade, William J. Irvin, Sreekanth C. Reddy, Jeffrey Crawford, Jeffrey D. Bradley, Thomas E. Stinchcombe, Suresh S. Ramalingam, Jieling Miao, Katherine Minichiello, Roy S. Herbst, Vassiliki A. Papadimitrakopoulou, Karen Kelly, David R. Gandara
Summary: The study found that the combination of Durvalumab and Tremelimumab had minimal activity in patients with advanced squamous non-small cell lung cancer, especially those who had received prior PD-1 therapy. There were also observed grade ≥ 3 adverse events in a portion of the patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
